A discounted, recurring-revenue diagnostics franchise trying to earn a re-rating by deleveraging fast enough to bridge a molecular “gap year” and launch LEX.
Overview
QuidelOrtho (QDEL) is a global in vitro diagnostics company created by the May 2022 merger of Quidel and Ortho Clinical Diagnostics, combining Quidel’s rapid point-of-care strengths with Ortho’s high-loyalty laboratory and transfusion medicine franchises. The business model is structurally resilient: instrument placements drive multi-year recurring consumables and service revenue, with roughly 90%–96% of sales classified as recurring, helping dampen macro cyclicality. The company sells into 130+ countries (North America ~59% of sales) and operates across four segments—Labs (VITROS systems), Point of Care (Sofia/QuickVue, Triage), Immunohematology (transfusion safety), and Molecular Diagnostics (resetting via LEX). In FY2025, reported revenue was ~$2.73B; respiratory-related sales declined ~20% as post-pandemic demand normalized, but the non-respiratory core grew ~5% CER, indicating underlying health. FY2025 was positioned as a “reset” year, including a $701M non-cash goodwill impairment and exits from non-core initiatives (e.g., U.S. Donor Screening), while operational performance improved: adjusted EBITDA rose to ~$597M with margin expanding ~240 bps to ~22% and adjusted EPS reaching ~$2.12. Free cash flow was negative (~-$77M) due largely to one-time ERP conversion costs, but management guides for a significant rebound in 2026 to $120–$160M as integration/ERP spending fades. The near-term focus is disciplined execution—deleveraging from ~4.2x net leverage, stabilizing core Labs growth, and advancing the LEX molecular platform as the key medium-term catalyst.